Risk of myocardial infarction persisting after discontinuation of non-steroidal anti-inflammatory drugs in the general population

被引：2
作者：
Garcia Rodriguez, L. A. [1 ]
Patrignani, P. [2 ,4 ]
Gonzalez-Perez, A. [1 ,3 ]
机构：
[1] CEIFE, Madrid 28004, Spain
[2] Univ G DAnnunzio, Sch Med, CeSI, Dept Med, Chieti, Italy
[3] Dept Struct Genom Neocodex, Seville, Spain
[4] Univ G DAnnunzio, Sch Med, CeSI, Ctr Excellence Aging, Chieti, Italy
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷 / 05期
关键词：
INHIBITORS PARECOXIB; ROFECOXIB; TRIAL; CYCLOOXYGENASE-2; VALDECOXIB; SURGERY;
D O I：
10.1111/j.1538-7836.2009.03321.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：892 / 894
页数：3
相关论文
共 14 条
  • [1] Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial
    Baron, John A.
    Sandler, Robert S.
    Bresalier, Robert S.
    Lanas, Angel
    Morton, Dion G.
    Riddell, Robert
    Iverson, Erik R.
    DeMets, David L.
    [J]. LANCET, 2008, 372 (9651) : 1756 - 1764
  • [2] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
    Bombardier, C
    Laine, L
    Reicin, A
    Shapiro, D
    Burgos-Vargas, R
    Davis, B
    Day, R
    Ferraz, MB
    Hawkey, CJ
    Hochberg, MC
    Kvien, TK
    Schnitzer, TJ
    Weaver, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) : 1520 - 1528
  • [3] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
    Bresalier, RS
    Sandler, RS
    Quan, H
    Bolognese, JA
    Oxenius, B
    Horgan, K
    Lines, C
    Riddell, R
    Morton, D
    Lanas, A
    Konstam, MA
    Baron, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) : 1092 - 1102
  • [4] Brun Johan, 2001, American Journal of Medicine, V110, p12S, DOI 10.1016/S0002-9343(00)00629-X
  • [5] Drug therapy: The coxibs, selective inhibitors of cyclooxygenase-2.
    FitzGerald, GA
    Patrono, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (06) : 433 - 442
  • [6] Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population
    Garcia Rodriguez, Luis Alberto
    Tacconelli, Stefania
    Patrignani, Paola
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (20) : 1628 - 1636
  • [7] Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
    Grosser, T
    Fries, S
    FitzGerald, GA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (01) : 4 - 15
  • [8] Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation -: An overview of epidemiologic studies published in the 1990s
    Hernández-Díaz, S
    Rodríguez, LAG
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (14) : 2093 - 2099
  • [9] Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction
    Hernández-Díaz, S
    Varas-Lorenzo, C
    Rodríguez, LAG
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 98 (03) : 266 - 274
  • [10] Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice
    Kobayashi, T
    Tahara, Y
    Matsumoto, M
    Iguchi, M
    Sano, H
    Murayama, T
    Arai, H
    Oida, H
    Yurugi-Kobayashi, T
    Yamashita, JK
    Katagiri, H
    Majima, M
    Yokode, M
    Kita, T
    Narumiya, S
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (06) : 784 - 794
12